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Introduction: An electronic clinical record (ECR) coding for all variables of CF and capturing ‘real time’ data from 2007 onwards 
was used as a basis for this study. From this data, longitudinal patterns of clinical variation have emerged that suggest a 
relationship between variation in lung function and adherence (Fig 1), where patterns of rapid improvements and decline could 
indicate poorer adherence to treatments when compared to a less variable picture. Adherence is difficult to measure with accuracy, 
prompting us to explore objective indicators that might aid early identification of patients who have difficulty in taking prescribed 
medications 
Fig 1 Longitudinal variation in lung function as shown on electronic clinical record       
 
 
 
  
The aim of the study was twofold 
a) To determine the accuracy of self-report adherence and its relationship with clinical variation  
b) To explore whether objective measures, including clinical variation can predict adherence. 
 
Methods: Patients aged 16 years and over attending an adult regional CF centre (total population n=420 patients) were invited to 
complete an adherence questionnaire (CFQ-R) and consent to pharmacy script data collection (previous 6 months). Coefficient of 
variation for FEV1 (CoV FEV1) was calculated from all contacts within the previous year.  
 The coefficient of variation (CV) was defined as the ratio of the standard deviation to the mean [CV = SD/mean] 
 We used data for 1 year prior to study enrolment using the highest and lowest values in trends over that 1 year period 
calculating mean and SD of these collated values for FEV1, Weight and CRP(See Figure) 
 
Age, gender, microbiology, disease severity (banding status), medication, lung function and weight were noted at baseline. Self-
reported adherence was calculated against prescribed medication (using ECR) and patients classified into one of 3 categories: low 
(<60%), moderate (60-80%), good (>80%) according to % calculated adherence. Ordinal regression was used to determine the 
contribution of age, gender, microbiology status, disease severity (Banding status), medication, genotype and CoV FEV1 to self-
reported adherence. 
Results: Patients (n=250) [age 29.7(±9.2) yrs, 58.6% (M), baseline BMI 22.5 kg/m2 (±3.8), FEV1 61.3% (±25.1), FVC 79.4% 
(±23.1)] completed the study. Pharmacy collection data was available for 106 (42%) patients. Pharmacy script collection was 
strongly correlated to self-reported adherence (Table 1). CoV FEV1 was inversely related to self-reported adherence (Table 1, Fig 
2). Conversely as adherence category improved, patients were noted to take greater numbers of medications. Regression analysis 
revealed that adjusting for disease severity CoV FEV1 [OR = 0. 95; CI: 0.92 to 0.99, p=0.016], number of types of medication [OR = 
1.2; CI: 1.1to 1.3, p<0.001], and age [OR = 1.04; CI: 1.01 to 1.07, p=0.01] together explained 24% of the variance in the model. 
Genotype, gender, microbiological status, were not individual predictors of adherence, nor did they contribute to the final model. 
Conclusion: Self-report adherence consistently exceeds medication collection by an average of 14%. Coefficient variation of FEV1 
may be an indirect measure of adherence and contributed to the final adherence model. In contrast to other studies medication load 
was greater as adherence category improved. Accurate longitudinal measures captured in ‘real time’ can aid in examining 
adherence and warrant further investigation.  
Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
*  p<0.05 
** p,0.001
Mean discrepancy 
between Self‐
reported adherence 
d h
  
 
Table 1  Correlations with self‐report adherence Descriptive statistics     
 Adherence 
Self‐Report 
(using CFQ‐
R) (%) 
Pharmacy 
script 
collection 
Sig Coefficient 
variation 
FEV1 
Sig Pharmacy script 
discrepancy (%)
Sig
Total adherence 77.7(±17.5) 0.61 P<0.001 ‐0.16 P<0.001 ‐14.3 p<0.001 
Aerosol to open airway 82.3(±31.9) 0.34 P<0.005 0.001 p=0.47 ‐4.5 p=0.24 
Aerosol to thin mucus 73.0(±37.8) 0.51 p<0.001 ‐0.11 p=0.06 ‐19.2 p<0.001 
Inhaler 77.4(±35.4) 0.51 p<0.001 ‐0.07 p=0.21 ‐16.2 p<0.001 
PERT 91.4(±21.3) 0.45 p<0.001 ‐0.21 P=0.001 ‐23.6 p<0.001 
Oral nutrition supplements 64.1(±39.8) 0.51 p<0.001 ‐0.20 P=0.01 ‐18.1 p<0.01 
Vitamins 88.2(±27.2) 0.46 p<0.001 ‐0.03 P=0.35 ‐24.7 p<0.001 
Oral antibiotics 86.4(±26.6) 0.32 p<0.001 ‐0.15 P=0.01 ‐19.5 p<0.001 
Nebulised antibiotics 67.4(±9.1) 0.55 p<0.001 ‐0.19 P=0.01 ‐2.1 P=0.43 
Figure 2  Changes in the 3 objective predictors of reported adherence within each adherence category 
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